keytruda

Eisai and Merck & Co., Inc. Present Results from Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

ruth 12 9 月

6 minutes

TOKYO and RAHWAY, N.J., Sep 12 […]

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial

ruth 4 8 月

4 minutes

TOKYO and RAHWAY, N.J., Aug 4, […]

LENVIMA in Combination with KEYTRUDA Approved In Taiwan for the Treatment of Patients with Advanced Endometrial Carcinoma

ruth 7 3 月

7 minutes

TOKYO, Mar 7, 2022 – (JC […]

Eisai: LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma

ruth 25 2 月

3 minutes

TOKYO and KENILWORTH, N.J., Fe […]

Eisai: Lenvima (Lenvatinib) in Combination with Keytruda (Pembrolizumab) Approved in Taiwan for the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma

ruth 31 1 月

8 minutes

TOKYO, Jan 31, 2022 – (J […]

Eisai: Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Advanced Endometrial Carcinoma

ruth 20 1 月

3 minutes

TOKYO, Jan 20, 2022 – (J […]

European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) for Patients With Certain Types of Endometrial Carcinoma

ruth 29 11 月

3 minutes

TOKYO and KENILWORTH, N.J., No […]

European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma

ruth 29 11 月

13 minutes

TOKYO and KENILWORTH, N.J., No […]

FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for First-Line Treatment of Adult Patients with Advanced Renal Cell Carcinoma (RCC)

ruth 12 8 月

18 minutes

TOKYO and KENILWORTH, N.J., Au […]

Eisai: FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma

ruth 23 7 月

5 minutes

TOKYO and KENILWORTH, N.J., Ju […]

Eisai: New Data on LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus Sunitinib

ruth 8 6 月

5 minutes

TOKYO and KENILWORTH, N.J., Ju […]

Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan

ruth 31 3 月

2 minutes

TOKYO, Mar 31, 2021 – (J […]

LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

ruth 15 2 月

4 minutes

TOKYO, Feb 15, 2021 – (J […]

LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in OS, PFS and ORR

ruth 17 12 月

4 minutes

TOKYO, Dec 17, 2020 – (J […]

Copyright © 2020 ASEANPR.Com All rights reserved.